Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
04/2003
04/15/2003CA2053208C Hydroxyalkylquinoline ether acids as leukotriene antagonists
04/15/2003CA2051504C 1-phenyl-3-aryl-2-propyne-1-ones as calcium uptake inhibitors
04/15/2003CA2037975C 5-hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors
04/10/2003WO2003029824A1 Method and agent for diagnosing and treating chronic inflammatory bowel diseases
04/10/2003WO2003029464A2 Genes associated with mast cell activation
04/10/2003WO2003029437A2 Secreted proteins
04/10/2003WO2003029436A2 Ul16 binding protein 4
04/10/2003WO2003029424A2 Novel proteins and nucleic acids encoding same
04/10/2003WO2003029423A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
04/10/2003WO2003029420A2 Apo-2 ligand variants and uses thereof
04/10/2003WO2003029412A2 Restricted expression lentivial vectors
04/10/2003WO2003029410A2 METHODS OF USING 69039, A NOVEL HUMAN Na/Ca EXCHANGER FAMILY MEMBER
04/10/2003WO2003029296A1 Human anti-cd40 antibodies
04/10/2003WO2003029293A2 Modulators of notch ic protease activity for use in immunotherapy
04/10/2003WO2003029289A2 Fragements of heat shock proteins and their use
04/10/2003WO2003029276A2 Copolymers for suppression of autoimmune diseases, and methods of use
04/10/2003WO2003029268A1 Androstane 17-beta-carboxamides as androgen receptor modulators
04/10/2003WO2003029245A1 Spiro-hydantoin compounds useful as anti-inflammatory agents
04/10/2003WO2003029242A1 NF-λB INHIBITORS
04/10/2003WO2003029205A1 Diaryl sulfide derivative, addition salt thereof, and immunosuppressant
04/10/2003WO2003029200A2 Compounds useful as reversible inhibitors of cysteine proteases
04/10/2003WO2003029184A1 Diaryl ether derivative, addition salt thereof, and immunosuppressant
04/10/2003WO2003028759A1 Rsv gene expression vaccine
04/10/2003WO2003028753A1 USE OF INTERFERON β IN THE THERAPY OF SYSTEMIC LUPUS ERYTHEMATODES
04/10/2003WO2003028752A1 Csf-1 immunomodulation
04/10/2003WO2003028748A1 A method of extracting deoxyadenosins components from cordyceps sinensis
04/10/2003WO2003028745A1 A composition for lowering the concentration of intestinal pathogenic peptides
04/10/2003WO2003028720A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
04/10/2003WO2003028712A2 Purinergic and pyrimidinergic receptor agonists for the treatment of activated cd4+ t lymphocyte-mediated immune diseases
04/10/2003WO2003028705A1 Pharmaceutical compositions comprising colloidal silicon dioxide
04/10/2003WO2003028673A1 Cosmetic preparation
04/10/2003WO2003028668A2 Gammaglobulin treatment of immune disorders
04/10/2003WO2003028656A2 Adjuvant compositions
04/10/2003WO2003028634A2 Method of treatment using ligand-immunogen conjugates
04/10/2003WO2003028630A2 Methods and compositions for modulating interleukin-21 receptor activity
04/10/2003WO2003028444A1 Nonhuman mammal model of autoimmune disease having ox40l gene transferred thereinto
04/10/2003WO2003017935A9 Human antibodies specific for interleukin 15 (il-15)
04/10/2003WO2003015711A9 Combination motif immune stimulatory oligonucleotides with improved activity
04/10/2003WO2003013564A3 An herbal composition for the treatment and remedy of bronchial respiratory difficulties
04/10/2003WO2003002598A3 Peptides for use as translocation factors
04/10/2003WO2003002092A3 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same
04/10/2003WO2003000709A9 Sialic acid derivatives for use as siglec inhibitors
04/10/2003WO2002102394A3 Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport
04/10/2003WO2002100348A8 Human monoclonal antibodies to epidermal growth factor receptor (egfr)
04/10/2003WO2002094830A8 Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists
04/10/2003WO2002094203A3 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
04/10/2003WO2002092064A3 Therapeutic method for inducing tolerance
04/10/2003WO2002083103A3 Pharmaceutical product with reticulated crystalline microstructure
04/10/2003WO2002080982A9 Nucleic acid mucosal immunization
04/10/2003WO2002074238A3 Water soluble and palatable complexes
04/10/2003WO2002071827A3 Retinoid x receptor modulators
04/10/2003WO2002059083A3 Novel compounds
04/10/2003WO2002055095A8 Use of aziridino-compounds in the treatment of immune dysfunctions
04/10/2003WO2002043745A3 Histaminase of vegetable origin for use in the treatment of allergic and septic shock and of allergic asthma
04/10/2003WO2002008396A3 Human proteases
04/10/2003WO2002000174A3 Compositions and methods for the therapy and diagnosis of lung cancer
04/10/2003WO2001092547A9 Modified bovine adenovirus having altered tropism
04/10/2003US20030069428 Pharmaceutically active isoindoline derivatives
04/10/2003US20030069424 Indolylmaleimide derivatives
04/10/2003US20030069406 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of blood disorders
04/10/2003US20030069315 New use for 1,3-propanediol derivatives
04/10/2003US20030069297 4-aryl substituted indolinones
04/10/2003US20030069288 Substituted aminomethyl-phenyl-cyclohexane derivatives
04/10/2003US20030069287 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
04/10/2003US20030069266 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
04/10/2003US20030069260 1-alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors
04/10/2003US20030069259 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
04/10/2003US20030069243 Novel substituted imidazole compounds
04/10/2003US20030069241 Analgesics; central nervous system disorders; gastrointestinal disorder; therapy for drug abruse ; antiinflammatory agents
04/10/2003US20030069238 Anticancer agents; immunology diseases; antiallergens; antiinflammatory agents
04/10/2003US20030069228 Capase inhibitors; antiinflammatory agents
04/10/2003US20030069224 Non-nucleoside reverse transcriptase inhibitors
04/10/2003US20030069210 Especially imidazolyl- or 1,2,4-triazolyl- pyrimidine derivatives
04/10/2003US20030069201 Methods of using BCL-2 for the therapeutic treatment and prevention of diseases
04/10/2003US20030069192 May be administered along with Rutin, a Rutin congener and/or a Rutin derivative.
04/10/2003US20030069181 Alternative splice forms of proteins as basis for multiple therapeutic modalities
04/10/2003US20030069169 Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders
04/10/2003US20030069168 Especially flavanoids or chromones containing a rhamnose group that have selective inhibitory activity against the activated T cells
04/10/2003US20030068812 Immune modulation device for use in animals
04/10/2003US20030068664 Monitoring effectiveness of preferential cancer immunotherapy; obtain mammal, administer immunotherapy, evaluate effectiveness of treatment
04/10/2003US20030068429 Inulin products with improved nutritional properties
04/10/2003US20030068387 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
04/10/2003US20030068363 Complexes consisting of an isolated major histocompatibility complex component and an autoantigenic peptide associated with the antigen binding site of the component; useful in treating autoimmune disease
04/10/2003US20030068340 Pharmaceutically non-toxic amount of an oligosaccharide capable of forming an association or complex with aqueous 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-(4-(2-morpholin -4-yl- ethoxy)-naphthalen-1-yl)-urea; antiinflammatories
04/10/2003US20030068336 Purified capsular polysaccharides from Neisseria meningitidis serogroups are activated and attached to a carriers protein
04/10/2003US20030068333 Cocktail of >/= 4 different plasmid DNAs encoding corresponding respiratory syncytial virus antigens, coacervated with chitosan to formulate nanospheres
04/10/2003US20030068320 Methods of administering/dosing CD2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
04/10/2003US20030068279 Dispersible pharmaceutical-based dry powder composition comprising a therapeutically effective amount of pharmaceutical in combination with a pharmaceutically acceptable carrier
04/10/2003US20030066524 Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage
04/10/2003CA2776522A1 Development of a preventive vaccine for filovirus infection in primates
04/10/2003CA2776391A1 Development of a preventive vaccine for filovirus infection in primates
04/10/2003CA2776272A1 Development of a preventive vaccine for filovirus infection in primates
04/10/2003CA2768340A1 Copolymers for suppression of autoimmune diseases, and methods of use
04/10/2003CA2466020A1 Rsv gene expression vaccine
04/10/2003CA2463404A1 Fragements of heat shock proteins and their use
04/10/2003CA2462795A1 Secreted proteins
04/10/2003CA2462790A1 Ul16 binding protein 4
04/10/2003CA2462682A1 The use of gammaglobulin for the treatment of immune-mediated diseases
04/10/2003CA2462628A1 Restricted expression lentiviral vectors
04/10/2003CA2462602A1 Double stranded rna as an adjuvant in vaccine compositions
1 ... 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 ... 1172